Document:

Exhibit 10.4

 

TERM
SHEET

CONVERTIBLE
PREFERRED EQUITY INVESTMENT IN

ONCOBIOLOGICS,
INC.

 

June
20, 2018

 

This
Term Sheet summarizes the principal terms of the agreement to exchange voting Series A Convertible Preferred Stock (“Series
A Preferred”) held by GMS Tenshi Holdings Pte. Ltd., a Singapore private limited company (“Investor”)
into newly created voting Series A-1 convertible preferred stock (the “Series A-1 Preferred”) of Oncobiologics,
Inc., a Delaware corporation (the “Company”). Such exchange is referred to herein as the “Transaction.”
This Term Sheet is solely intended as a basis for further discussion between Investor and the Company and is not intended to be
a complete description of the proposed Transaction and does not address all the items that the parties would need to agree on
before entering into a definitive exchange agreement. Except for sections titled “Fees and Expenses,” “Confidentiality”,
 “Authority; Efforts” and “Governing Law” below, which constitute binding agreements and
obligations of the parties, this Term Sheet does not constitute a legally binding obligation on the part of Investor or the Company.

 

	Securities Exchange	Following conversion of 208,836 shares of Series A Preferred held by Investor on June 20, 2018, Investor will exchange its remaining 52,209 shares of Series A Preferred for Series A-1 Preferred.
	 	 
	Series A-1 Terms	
        Substantially identical to the existing Series A Preferred, subject
        to:

         

        ·     Redemption
        premium increased to $600.00 per share;

        ·     Liquidation
        preference increased to $550.00 per share;

        ·     Conversion
        into Company common stock/Voting rights subject to restriction in the event such action would violate applicable Nasdaq rules absent
        stockholder approval; and

        ·     Such
        other changes as may be necessary or appropriate to put the Investor in a similar financial position to its position under the
        Series A Preferred held immediately prior to the conversion described herein (other than increases to the interest or modifications
        to the Series A Conversion Rate).

	 	 
	Nasdaq	Entry into binding definitive agreement subject to Nasdaq notification of listing of additional shares and other requirements if such Series A-1 Preferred is convertible into/represents more than 10% pre-transaction outstanding voting power.
	 	 
	Investor Rights Agreement	To be amended to extend rights to shares of Common Stock issuable upon conversion of Series A-1 Preferred.

 

    	 	 	 

     

    

	 	 
	Documentation	Documentation required to effect the transaction
    will be on customary terms and will include an exchange agreement, certificate of designation, amendment of investor rights
    agreement, and such other documents and agreements (including any amendments or modifications to existing documents or agreements
    between the Investor and the Company) as are required by the Investor to effectuate the purpose of this exchange and as are
    reasonably necessary or appropriate.  
	 	 
	Fees and Expenses	In
        consideration of the significant time and resources expended to date and to be expended by the Investor with respect to
        the transactions as described in this Term Sheet, regardless of whether the transactions contemplated by this Term Sheet
        are consummated, the Company shall pay and reimburse Investor for, and Investor shall be entitled to, all reasonable and
        documented out of pocket fees and expenses incurred by the Investor in connection with the negotiation, execution, diligence,
        evaluation and structuring of this Transaction (including costs of recovering any such fees or expenses from the Company
        in a dispute or otherwise).

         

        If
        Investor has converted at least 208,836 shares of Series A Preferred into Company common stock on or prior to June 21,
        2018, and the exchange of the remaining issued and outstanding shares of Series A Preferred held by Investor for newly
        created Series A-1 Preferred on substantially the terms as contemplated hereby shall not have occurred on or prior to
        July 20, 2018, the Transaction shall be terminated and abandoned without any further action required by either the Investor
        or the Company, the unconverted Series A Preferred then held by Investor will remain issued and outstanding and governed
        by its terms, and Investor shall be entitled to payment by the Company of a conversion premium equal to $10 million (as
        liquidated damages) via wire transfer of immediately available funds to an account designated by the Investor in writing
        within two Business Days of such termination and abandonment in lieu of any such exchange.

	 	 
	Confidentiality	The existence and terms of this Term Sheet shall
    not be disclosed to a third party by Investor or the Company unless such party reasonably determines (based upon advice of
    outside counsel) that disclosure of the existence or terms of this Term Sheet is required by law.  In such event,
    the party proposing to disclose the existence or terms of this Term Sheet shall provide the other party with as much prior
    notice as is practicable.
	 	 
	Authority; Efforts	This Term Sheet and the proposed Transaction
    contemplated hereby have been duly approved by the Company’s special finance committee, including the binding provisions
    hereof.  No other approvals or consents are required by the Company.  The Company’s special finance
    committee has authorized the officers of the Company to execute this Term Sheet and to negotiate, memorialize and execute
    the proposed Transaction and to carry out the purpose of this Term Sheet.  The Company hereby agrees to use its
    reasonable best efforts acting in good faith to negotiate and execute the Transaction within 30 calendar days of the date
    hereof.

 

    	 	2	 

     

    

 

	Governing Law	This
        Term Sheet is governed by the laws of the State of New York.

         

        Each
        of the parties to this letter agreement hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction
        of the courts of the State of New York and the United States of America, in each case located in the County of New York,
        for any actions, suits or proceedings arising out of or relating to this letter agreement (and each such party agrees
        not to commence any action, suit or proceeding relating thereto except in such courts), and further agrees that service
        of any process, summons, notice or document by United States registered mail to its address set forth above shall be effective
        service of process for any action, suit or proceeding brought against such party in any such court. Each of the parties
        to this letter agreement hereby irrevocably and unconditionally waives any objection to the laying of venue of any action,
        suit or proceeding arising out of this letter agreement, in the courts of the State of New York and the United States
        of America, in each case located in the County of New York, and hereby further irrevocably and unconditionally waives
        and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court
        has been brought in an inconvenient forum.

 

    	 	3	 

     

    

  

IN
WITNESS WHEREOF, the parties hereto have caused this Term Sheet to be executed as of the date first written above.

 

	 	INVESTOR:
	 	 
	 	GMS TENSHI HOLDINGS PTE. LTD.

 

	 	By:	/s/ Faisal Sukhtian
	 	 
	 	Name:	 
	 	 
	 	Title:  	 

 

	 	COMPANY:
	 	 
	 	ONCOBIOLOGICS, INC.

 

	 	By:	/s/
    Lawrence A. Kenyon
	 	 
	 	Name:	Lawrence
    A. Kenyon
	 	 
	 	Title:  	CFO                                                   

 

    	 	4Exhibit 10.5

 

SEPARATION
AGREEMENT AND RELEASE

 

This
Separation Agreement and Release (“Agreement”) is made by and between Pankaj Mohan, Ph.D. (“Employee”)
and Oncobiologics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred
to as a “Party”).

 

RECITALS

 

WHEREAS,
Employee was employed by the Company;

 

WHEREAS,
Employee is a shareholder of the Company and serves on the Board of Directors of the Company (the “Board”);

 

WHEREAS,
Employee signed an Executive Employment Agreement with the Company on or about February 22, 2016 (the “Offer Letter”);

 

WHEREAS,
Employee signed an Employee Proprietary Information, Inventions, Non-Solicitation and Non-Competition Agreement with the Company
on February 22, 2016 (the “Confidentiality Agreement”);

 

WHEREAS,
the Company and Employee entered into an Indemnity Agreement (the “Indemnity Agreement”);

 

WHEREAS,
Employee separated from employment with the Company effective June 18, 2018 (the “Separation Date”);

 

WHEREAS,
contemporaneously with this Agreement, Employee will enter into a Consulting Agreement with the Company (the “Consulting
Agreement”), and

 

WHEREAS,
the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that
the Employee may have against the Company and any of the Releasees as defined below, arising out of or related to Employee’s
employment with or separation from the Company;

 

WHEREAS,
the Parties agree that this Agreement shall not limit Employee’s rights as a shareholder or Board member.

 

NOW,
THEREFORE, in consideration of the mutual promises made herein, the Company and Employee hereby agree as follows:

 

COVENANTS

 

1.       Consideration.
In consideration of Employee’s execution of this Agreement and Employee’s fulfillment of all of its terms and conditions,
and provided that Employee does not revoke the Agreement under Section 5 below, the Company agrees as follows:

 

a.     Initial
Salary Payment. The Company agrees to pay Employee a lump sum approximately equivalent to six (6) months of Employee’s
base salary, for a total of Two Hundred Forty Five Thousand Dollars ($245,000.00), less applicable withholding, within ten (10)
business days after the Effective Date of this Agreement.

 

b.     Initial
Bonus Payment. The Company agrees to pay Employee a lump sum approximately equivalent to 50% of Employee’s 2018 Target
Bonus, for a total of One Hundred Twenty Two Thousand Five Hundred Dollars ($122,500.00), less applicable withholding, within
ten (10) business days after the Effective Date of this Agreement.

 

c.     Second
Salary Payment. The Company agrees to pay Employee a lump sum approximately equivalent to six (6) months of Employee’s
base salary, for a total of Two Hundred Forty Five Thousand Dollars ($245,000.00), less applicable withholding, by no later than
January 4, 2019.

 

    			 

     

    

 

d.     Second
Bonus Payment. The Company agrees to pay Employee a lump sum approximately equivalent to 50% of Employee’s 2018 Target
Bonus, for a total of One Hundred Twenty Two Thousand Five Hundred Dollars ($122,500.00), less applicable withholding, by no later
than January 4, 2019.

 

e.     COBRA.
The Company shall reimburse Employee for the payments Employee makes for COBRA coverage for a period of twelve (12) months, or
until Employee has secured other full-time employment, whichever occurs first, provided Employee timely elects and pays for COBRA
coverage. COBRA reimbursements shall be made by the Company to Employee consistent with the Company’s normal expense reimbursement
policy, provided that Employee submits documentation to the Company substantiating Employee’s payments for COBRA coverage.

 

f.     General.
Employee specifically acknowledges and agrees that the consideration provided to Employee
hereunder fully satisfies any obligation that the Company had to pay Employee wages, severance, separation pay, or any other compensation
for any of the services that Employee rendered to the Company or pursuant to any express or implied Company contract, that the
amount paid is in excess of any disputed wage claim or claim for severance or separation pay that Employee may have, that the
consideration paid shall be deemed to be paid first in satisfaction of any disputed wage claim or claim for severance or separation
pay with the remainder sufficient to act as consideration for the release of claims set forth herein, and that Employee has not
earned and is not entitled to receive any additional wages, severance, separation pay, or other form of compensation from the
Company. Employee acknowledges and agrees that without this Agreement,
Employee is otherwise not entitled to the consideration listed in this Section 1.

 

2.       Benefits.
Employee’s health insurance benefits shall cease on the Separation Date, unless otherwise stated in the Company’s
health insurance plan documents and subject to Employee’s right to continue Employee’s health insurance under COBRA.
Employee’s participation in all benefits and incidents of employment, including, but not limited to, vesting in stock options,
and the accrual of bonuses, vacation, and paid time off, ceased as of the Separation Date.

 

3.       Payment
of Salary and Receipt of All Benefits. Employee acknowledges and represents that, other than the consideration set forth in
this Agreement, the Company and its agents have paid or provided all salary, wages, bonuses, accrued vacation/paid time off, notice
periods, premiums, leaves, housing allowances, relocation costs, interest, severance, outplacement costs, fees, reimbursable expenses,
commissions, stock, stock options, vesting, and any and all other benefits and compensation due to Employee.

 

4.       Release
of Claims. Employee agrees that the foregoing consideration represents settlement in full of all outstanding obligations owed
to Employee by the Company and its current and former officers, directors, employees, agents, investors, attorneys, shareholders,
administrators, affiliates, benefit plans, plan administrators, professional employer organization or co-employer, insurers, trustees,
divisions, and subsidiaries, and predecessor and successor corporations and assigns (collectively, the “Releasees”).
Employee, on Employee’s own behalf and on behalf of Employee’s respective heirs, family members, executors, agents,
and assigns, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute,
prosecute, or pursue, any claim, complaint, charge, duty, obligation, demand, or cause of action relating to any matters of any
kind, whether presently known or unknown, suspected or unsuspected, that Employee may possess against any of the Releasees arising
from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Agreement, including,
without limitation:

 

a.     any
and all claims relating to or arising from Employee’s employment relationship with the Company and the termination of that
relationship;

 

b.     any
and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment; retaliation;
breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory
estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional misrepresentation; negligent
or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander;
negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits;

 

    	 	Page 2 of 8	 

     

    

 

c.     any
and all claims for violation of any federal, state, or municipal statute, including, but not limited to, Title VII of the
Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of
1990; the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act
of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment
and Retraining Notification Act; the Family and Medical Leave Act; the Uniformed Services Employment and Reemployment Rights Act;
the New Jersey Law Against Discrimination; the New Jersey Equal Pay Act; the New Jersey Conscientious Employee Protection Act;
the New Jersey Civil Rights Act; the New Jersey Family Leave Act; the New Jersey State Wage and Hour Law; and the
New Jersey Wage Withholding Protection Law.

 

d.     any
and all claims for violation of the federal or any state constitution;

 

e.     any
and all claims arising out of any other laws and regulations relating to employment or employment discrimination;

 

f.     any
claim for any loss, cost, damage, or expense arising out of any dispute over the nonwithholding or other tax treatment of any
of the proceeds received by Employee as a result of this Agreement; and

 

g.     any
and all claims for attorneys’ fees and costs.

 

Employee agrees
that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the
matters released. This release does not extend to any obligations incurred under this Agreement. This release does not release
claims that cannot be released as a matter of law, including any Protected Activity (as defined below). This release does not
extend to any right Employee may have to unemployment compensation benefits or workers’ compensation benefits. Employee
represents that Employee has made no assignment or transfer of any right, claim, complaint, charge, duty, obligation, demand,
cause of action, or other matter waived or released by this Section.

 

5.       Acknowledgment
of Waiver of Claims under ADEA. Employee acknowledges that Employee is waiving and releasing any rights Employee may have
under the Age Discrimination in Employment Act of 1967 ("ADEA"), and that this waiver and release is knowing and voluntary.
Employee agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective
Date of this Agreement. Employee acknowledges that the consideration given for this waiver and release is in addition to anything
of value to which Employee was already entitled. Employee further acknowledges that Employee has been advised by this writing
that: (a) Employee should consult with an attorney prior to executing this Agreement; (b) Employee has twenty-one (21)
days within which to consider this Agreement; (c) Employee has seven (7) days following Employee’s execution of this Agreement
to revoke this Agreement; (d) this Agreement shall not be effective until after the revocation period has expired; and (e) nothing
in this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of
this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically
authorized by federal law. In the event Employee signs this Agreement and returns it to the Company in less than the 21-day period
identified above, Employee hereby acknowledges that Employee has freely and voluntarily chosen to waive the time period allotted
for considering this Agreement. Employee acknowledges and understands that revocation must be accomplished by a written notification
to the undersigned Company representative that is received prior to the Effective Date. The Parties agree that changes, whether
material or immaterial, do not restart the running of the 21-day period.

 

6.       No
Pending or Future Lawsuits. Employee represents that Employee has no lawsuits, claims, or actions pending in Employee’s
name, or on behalf of any other person or entity, against the Company or any of the other Releasees. Employee also represents
that Employee does not intend to bring any claims on Employee’s own behalf or on behalf of any other person or entity against
the Company or any of the other Releasees.

 

7.       Application
for Employment. Employee understands and agrees that, as a condition of this Agreement, Employee shall not be entitled to
any employment with the Company, and Employee hereby waives any right, or alleged right, of employment or re-employment with the
Company. Employee further agrees not to apply for employment with the Company and not otherwise pursue an independent contractor
or vendor relationship with the Company, except as agreed upon by the Parties in the Consulting Agreement.

 

    	 	Page 3 of 8	 

     

    

 

8.       Confidentiality.
Employee agrees to maintain in complete confidence the existence of this Agreement, the contents and terms of this Agreement,
and the consideration for this Agreement (hereinafter collectively referred to as “Separation Information”). Except
as required by law, Employee may disclose Separation Information only to Employee’s immediate family members, the Court
in any proceedings to enforce the terms of this Agreement, Employee’s counsel, and Employee’s accountant and any professional
tax advisor to the extent that they need to know the Separation Information in order to provide advice on tax treatment or to
prepare tax returns, and must prevent disclosure of any Separation Information to all other third parties. Employee agrees that
Employee will not publicize, directly or indirectly, any Separation Information.

 

9.       Trade
Secrets and Confidential Information/Company Property. Employee reaffirms and agrees to observe and abide by the terms of
the Confidentiality Agreement, specifically including the provisions therein regarding nondisclosure of the Company’s trade
secrets and confidential and proprietary information, with the exception of the provisions concerning noncompetition and nonsolicitation
of Company employees, which are hereby superseded by Section 10 of this Agreement. Employee agrees that the above reaffirmation
and agreement with the Confidentiality Agreement shall constitute a new and separately enforceable agreement to abide by the terms
of the Confidentiality Agreement, entered and effective as of the Effective Date. Employee specifically acknowledges and agrees
that any violation of the restrictive covenants in the Confidentiality Agreement and/or this Agreement shall constitute a material
breach of this Agreement. Employee’s signature below constitutes Employee’s certification under penalty of perjury
that Employee has returned all documents and other items provided to Employee by the Company, developed or obtained by Employee
in connection with Employee’s employment with the Company, or otherwise belonging to the Company, including, but not limited
to, all passwords to any software or other programs or data that Employee used in performing services for the Company.

 

10.      Covenant
Not to Compete and No Solicitation

 

A.     Covenant
Not to Compete – Advanced Products.  Employee agrees for a period beginning on the Effective Date and terminating on
the date that is forty-eight (48) months after the date on which (y) Employee ceases being a director of the Company, or (z) the
Consulting Agreement is terminated, whichever is later, Employee will not, without the prior written consent of the Company, directly
or indirectly, whether paid or not: (i) serve as a partner, principal, licensor, licensee, employee, consultant, officer, director,
manager, agent, affiliate, representative, advisor, promoter, associate, or investor for, (ii) directly or indirectly, own, purchase,
organize or take preparatory steps for the organization of, or (iii) build, design, finance, acquire, lease, operate, manage,
control, invest in, work or consult for or otherwise join, participate in or affiliate Employee with, any business whose business,
products or operations involve the development, sale, or marketing of products the same as or similar to the Company’s ONS-1045
or other Avastin biosimilars, ONS-3010 or other Humira biosimilars, and ONS-5010.

 

B.     Covenant
Not to Compete – Other Products.  Employee agrees for a period beginning on the Effective Date and terminating on the
date that is twelve (12) months after the date on which (y) Employee ceases being a director of the Company, or (z) the Consulting
Agreement is terminated, whichever is later, Employee will not, without the prior written consent of the Company, directly or
indirectly, whether paid or not: (i) serve as a partner, principal, licensor, licensee, employee, consultant, officer, director,
manager, agent, affiliate, representative, advisor, promoter, associate, or investor for, (ii) directly or indirectly, own, purchase,
organize or take preparatory steps for the organization of, or (iii) build, design, finance, acquire, lease, operate, manage,
control, invest in, work or consult for or otherwise join, participate in or affiliate Employee with, any business whose business,
products or operations involve the development, sale, or marketing of products the same as or similar to the Company’s Prolia
or Stelara biosimilar products.

 

C.     No
Solicitation of Employees.  Employee agrees for a period beginning on the Effective Date and terminating on the date that
is twelve (12) months after the date on which (y) Employee ceases being a director of the Company, or (z) the Consulting Agreement
is terminated, whichever is later, Employee will not directly or indirectly hire, solicit, or recruit, or attempt to hire, solicit,
or recruit, any employee of the Company to leave their employment with the Company, nor will Employee contact any employee of
the Company, or cause an employee of the Company to be contacted, for the purpose of leaving employment with the Company.

 

D.     Acknowledgements.
In the event of Employee’s breach or violation of this Section 10, or good faith allegation by the Company of my breach
or violation of this Section, the restricted periods set forth in this Section shall be tolled until such breach or violation,
or dispute related to an allegation by the Company that Employee has breached or violated this Section, has been duly cured or
resolved, as applicable. The covenants contained in subsections (A), (B), and (C) above shall be construed as a series of separate
covenants, one for each city, county and state of any geographic area in the Territory.  Except for geographic coverage,
each such separate covenant shall be deemed identical in terms to the covenant contained in subsections (A), (B), and (C) above. 
If, in any judicial or arbitral proceeding, a court or arbitrator refuses to enforce any of such separate covenants (or any part
thereof), then such unenforceable covenant (or such part) shall be revised, or if revision is not permitted it shall be eliminated
from this Agreement, to the extent necessary to permit the remaining separate covenants (or portions thereof) to be enforced. 
In the event that the provisions of subsections (A), (B), and (C) above are deemed to exceed the time, geographic or scope limitations
permitted by applicable law, then such provisions shall be reformed to the maximum time, geographic or scope limitations, as the
case may be, then permitted by such law.

 

    	 	Page 4 of 8	 

     

    

 

11.      No
Cooperation. Employee agrees that Employee will not knowingly encourage, counsel, or assist any attorneys or their clients
in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party
against any of the Releasees, unless under a subpoena or other court order to do so or as related directly to the ADEA waiver
in this Agreement. Employee agrees both to immediately notify the Company upon receipt of any such subpoena or court order, and
to furnish, within three (3) business days of its receipt, a copy of such subpoena or other court order. If approached by anyone
for counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints
against any of the Releasees, Employee shall state no more than that Employee cannot provide counsel or assistance.

 

12.      Nondisparagement.
Employee agrees to refrain from any disparagement, defamation, libel, or slander of any of the Releasees, and agrees to refrain
from any tortious interference with the contracts and relationships of any of the Releasees. The Company agrees to refrain from
any disparagement, defamation, libel, or slander of Employee, and agrees to refrain from any tortious interference with the contracts
and relationships of Employee. The Parties understand and agree that the Company’s obligations under this Agreement apply
to its officers and directors and only for so long as each remains employed by or affiliated with the Company. Employee shall
direct any inquiries by potential future employers to the Company’s human resources department, which shall provide only
the Employee’s last position and dates of employment.  Employee’s violation of this provision shall be a material
breach of this Agreement. 

 

13.      Breach.
In addition to the rights provided in the “Attorneys’ Fees” section below, Employee acknowledges and agrees
that any material breach of this Agreement, unless such breach constitutes a legal action by Employee challenging or seeking a
determination in good faith of the validity of the waiver herein under the ADEA, or of any provision of the Confidentiality Agreement
shall entitle the Company immediately to recover and/or cease providing the consideration provided to Employee under this Agreement
and to obtain damages, except as provided by law, provided, however, that the Company shall not recover One Hundred
Dollars ($100.00) of the consideration already paid pursuant to this Agreement and such amount shall serve as full and complete
consideration for the promises and obligations assumed by Employee under this Agreement and the Confidentiality Agreement.

 

14.      No
Admission of Liability. Employee understands and acknowledges that this Agreement constitutes a compromise and settlement
of any and all actual or potential disputed claims by Employee. No action taken by the Company hereto, either previously or in
connection with this Agreement, shall be deemed or construed to be (a) an admission of the truth or falsity of any actual
or potential claims or (b) an acknowledgment or admission by the Company of any fault or liability whatsoever to Employee
or to any third party.

 

15.      Costs.
The Parties shall each bear their own costs, attorneys’ fees, and other fees incurred in connection with the preparation
of this Agreement.

 

16.      ARBITRATION.
THE PARTIES AGREE THAT ANY AND ALL DISPUTES ARISING OUT OF THE TERMS OF THIS AGREEMENT, THEIR INTERPRETATION, AND ANY OF THE MATTERS
HEREIN RELEASED, SHALL BE SUBJECT TO ARBITRATION IN MIDDLESEX COUNTY, BEFORE THE JUDICIAL ARBITRATION AND MEDIATION SERVICE (“JAMS”)
UNDER ITS COMPREHENSIVE ARBITRATION RULES (“JAMS RULES”) AND NEW JERSEY LAW. THE ARBITRATOR MAY GRANT INJUNCTIONS
AND OTHER RELIEF IN SUCH DISPUTES. THE ARBITRATOR SHALL ADMINISTER AND CONDUCT ANY ARBITRATION IN ACCORDANCE WITH NEW JERSEY LAW,
AND THE ARBITRATOR SHALL APPLY SUBSTANTIVE AND PROCEDURAL NEW JERSEY LAW TO ANY DISPUTE OR CLAIM, WITHOUT REFERENCE TO ANY CONFLICT-OF-LAW
PROVISIONS OF ANY JURISDICTION. TO THE EXTENT THAT THE JAMS RULES CONFLICT WITH NEW JERSEY LAW, NEW JERSEY LAW SHALL TAKE PRECEDENCE.
THE DECISION OF THE ARBITRATOR SHALL BE FINAL, CONCLUSIVE, AND BINDING ON THE PARTIES TO THE ARBITRATION. THE PARTIES AGREE THAT
THE PREVAILING PARTY IN ANY ARBITRATION SHALL BE ENTITLED TO INJUNCTIVE RELIEF IN ANY COURT OF COMPETENT JURISDICTION TO ENFORCE
THE ARBITRATION AWARD. THE PARTIES TO THE ARBITRATION SHALL EACH PAY HALF THE COSTS AND EXPENSES OF SUCH ARBITRATION, AND EACH
PARTY SHALL SEPARATELY PAY FOR ITS RESPECTIVE COUNSEL FEES AND EXPENSES; PROVIDED, HOWEVER, THAT THE ARBITRATOR SHALL AWARD ATTORNEYS’
FEES AND COSTS TO THE PREVAILING PARTY, EXCEPT AS PROHIBITED BY LAW. THE PARTIES AGREE THAT PUNITIVE DAMAGES SHALL BE UNAVAILABLE
IN ARBITRATION. THE PARTIES HEREBY AGREE TO WAIVE THEIR RIGHT TO HAVE ANY DISPUTE BETWEEN THEM RESOLVED IN A COURT OF LAW BY A
JUDGE OR JURY. NOTWITHSTANDING THE FOREGOING, THIS SECTION WILL NOT PREVENT EITHER PARTY FROM SEEKING INJUNCTIVE RELIEF (OR ANY
OTHER PROVISIONAL REMEDY) FROM ANY COURT HAVING JURISDICTION OVER THE PARTIES AND THE SUBJECT MATTER OF THEIR DISPUTE RELATING
TO THIS AGREEMENT AND THE AGREEMENTS INCORPORATED HEREIN BY REFERENCE. SHOULD ANY PART OF THE ARBITRATION AGREEMENT CONTAINED
IN THIS PARAGRAPH CONFLICT WITH ANY OTHER ARBITRATION AGREEMENT BETWEEN THE PARTIES, THE PARTIES AGREE THAT THIS ARBITRATION AGREEMENT
SHALL GOVERN.

 

    	 	Page 5 of 8	 

     

    

 

17.      Authority.
The Company represents and warrants that the undersigned has the authority to act on behalf of the Company and to bind the Company
and all who may claim through it to the terms and conditions of this Agreement. Employee represents and warrants that Employee
has the capacity to act on Employee’s own behalf and on behalf of all who might claim through Employee to bind them to the
terms and conditions of this Agreement. Each Party warrants and represents that there are no liens or claims of lien or assignments
in law or equity or otherwise of or against any of the claims or causes of action released herein.

 

18.      Protected
Activity. Employee understands that nothing in this Agreement shall in any way limit or prohibit Employee from engaging for
a lawful purpose in any Protected Activity, provided, however, that Employee agrees not to seek or accept any monetary award from
such a proceeding (except with respect to proceedings before the Securities and Exchange Commission). For purposes of this Agreement,
 “Protected Activity” shall mean filing a charge, complaint, or report with, or otherwise communicating with, cooperating
with or participating in any investigation or proceeding that may be conducted by, any federal, state or local government agency
or commission, including the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational
Safety and Health Administration, and the National Labor Relations Board (“Government Agencies”). Employee understands
that in connection with such Protected Activity, Employee is permitted to disclose documents or other information as permitted
by law, and without giving notice to, or receiving authorization from, the Company. Notwithstanding the foregoing, Employee agrees
to take all reasonable precautions to prevent any unauthorized use or disclosure of any information that may constitute Company
confidential information under the Confidentiality Agreement to any parties other than the relevant Government Agencies. Employee
further understands that “Protected Activity” does not include the disclosure of any Company attorney-client privileged
communications, and that any such disclosure without the Company’s written consent shall constitute a material breach of
this Agreement. In addition, pursuant to the Defend Trade Secrets Act of 2016, Employee is notified that an individual will not
be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i)
is made in confidence to a federal, state, or local government official (directly or indirectly) or to an attorney solely
for the purpose of reporting or investigating a suspected violation of law, or (ii) is made in a complaint or other document filed
in a lawsuit or other proceeding, if (and only if) such filing is made under seal. In addition, an individual who files a lawsuit
for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the individual’s
attorney and use the trade secret information in the court proceeding, if the individual files any document containing the trade
secret under seal and does not disclose the trade secret, except pursuant to court order.

 

19.      No
Representations. Employee represents that Employee has had an opportunity to consult with an attorney, and has carefully read
and understands the scope and effect of the provisions of this Agreement. Employee has not relied upon any representations or
statements made by the Company that are not specifically set forth in this Agreement.

 

20.      Severability.
In the event that any provision or any portion of any provision hereof or any surviving agreement made a part hereof becomes or
is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue
in full force and effect without said provision or portion of provision.

 

21.      Attorneys’
Fees. Except with regard to a legal action challenging or seeking a determination in good faith of the validity of the waiver
herein under the ADEA, in the event that either Party brings an action to enforce or effect its rights under this Agreement, the
prevailing Party shall be entitled to recover its costs and expenses, including the costs of mediation, arbitration, litigation,
court fees, and reasonable attorneys’ fees incurred in connection with such an action.

 

    	 	Page 6 of 8	 

     

    

 

22.      Entire
Agreement. This Agreement represents the entire agreement and understanding between the Company and Employee concerning the
subject matter of this Agreement and Employee’s employment with and separation from the Company and the events leading thereto
and associated therewith, and supersedes and replaces any and all prior agreements and understandings concerning the subject matter
of this Agreement and Employee’s employment with the Company, including the Executive Employment Agreement and the Indemnity
Agreement, with the exception of the arbitration provision in the Executive Employment Agreement, any provision of the Indemnity
Agreement that applies to Employee’s position as a director on the Board, the Confidentiality Agreement, Consulting Agreement,
and any agreements between the Company and Employee relating to stock or stock options or his position as a director on the Board.

 

23.      No
Oral Modification. This Agreement may only be amended in a writing signed by Employee and the Company’s Chief Executive
Officer.

 

24.      Governing
Law. This Agreement shall be governed by the laws of the State of New Jersey, without regard for choice-of-law provisions.
Employee consents to personal and exclusive jurisdiction and venue in the State of New Jersey.

 

25.      Effective
Date. Employee understands that this Agreement shall be null and void if not executed by Employee, and returned to the Company,
within the twenty-one (21) day period set forth above. Each Party has seven (7) days after that Party signs this Agreement to
revoke it. This Agreement will become effective on the eighth (8th) day after Employee signed this Agreement, so long as it has
been signed by the Parties and has not been revoked by either Party before that date (the “Effective Date”).

 

26.      Counterparts.
This Agreement may be executed in counterparts and each counterpart shall be deemed an original and all of which counterparts
taken together shall have the same force and effect as an original and shall constitute an effective, binding agreement on the
part of each of the undersigned. The counterparts of this Agreement may be executed and delivered by facsimile, photo, email PDF,
Docusign/Echosign or a similarly accredited secure signature service, or other electronic transmission or signature. This Agreement
may be executed in one or more counterparts, and counterparts may be exchanged by electronic transmission (including by email),
each of which will be deemed an original, but all of which together constitute one and the same instrument.

 

27.      Voluntary
Execution of Agreement. Employee understands and agrees that Employee executed this Agreement voluntarily, without any duress
or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Employee’s
claims against the Company and any of the other Releasees. Employee acknowledges that:

 

		(a)	Employee has
read this Agreement;

 

		(b)	Employee has
been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of Employee’s own choice
or has elected not to retain legal counsel;

 

		(c)	Employee understands
the terms and consequences of this Agreement and of the releases it contains; and

 

		(d)	Employee is
fully aware of the legal and binding effect of this Agreement.

 

    	 	Page 7 of 8	 

     

    

 

IN WITNESS WHEREOF,
the Parties have executed this Agreement on the respective dates set forth below.

 

	 	 	 	Pankaj Mohan, an individual
	 	 	 	 
	Dated:	
        1st
        July 2018              
	 	/s/ Pankaj Mohan
	 	 	 	Pankaj Mohan, Ph.D.
	 	 	 	 
	 	 	 	Oncobiologics, Inc.
	 	 	 	 
	Dated:	
        July
        2, 2018             
	 	By 	
        /s/
        Lawrence A. Kenyon

	 	
	 	 	Lawrence A. Kenyon
	 	
	 	 	CFO

  

    	 	Page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]